Figure 39. Forest plot of effects of therapy by drug class on flushing. This figure shows a forest plot from 10 RCTs representing 2113 patients assessed the incidence of flushing within the first 8 to 16 weeks of initiating therapy. Meta-analysis of these studies suggest an approximately two-fold increase in the risk of flushing associated with both endothelin antagonists (OR 2.63; 95% CI, 0.94 to 7.40) and phosphodiesterase inhibitors (OR 2.46; CI, 1.27 to 4.75), but the 95-percent confidence interval of the summary estimate for endothelin antagonists includes 1.0. The risk of jaw pain was also elevated with aerosolized prostanoids (OR 4.72; CI, 2.13 to 10.42).

Figure 39Forest plot of effects of therapy by drug class on flushing

CI = confidence interval; ERA = endothelin receptor antagonist; PDE5 = phosphodiesterase type 5 inhibitor

From: Results

Cover of Pulmonary Arterial Hypertension: Screening, Management, and Treatment
Pulmonary Arterial Hypertension: Screening, Management, and Treatment [Internet].
Comparative Effectiveness Reviews, No. 117.
McCrory DC, Coeytaux RR, Schmit KM, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.